- Home
- NUVB vs SXC Comparison
NUVB vs SXC Comparison
Compare NUVB & SXC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUVB
- SXC
- Stock Information
- Founded
- NUVB 2018
- SXC 1960
- Country
- NUVB United States
- SXC United States
- Employees
- NUVB N/A
- SXC N/A
- Industry
- NUVB Biotechnology: Pharmaceutical Preparations
- SXC Steel/Iron Ore
- Sector
- NUVB Health Care
- SXC Industrials
- Exchange
- NUVB Nasdaq
- SXC Nasdaq
- Market Cap
- NUVB 679.9M
- SXC 802.2M
- IPO Year
- NUVB N/A
- SXC N/A
- Fundamental
- Price
- NUVB $1.77
- SXC $9.21
- Analyst Decision
- NUVB Strong Buy
- SXC Strong Buy
- Analyst Count
- NUVB 6
- SXC 1
- Target Price
- NUVB $8.33
- SXC $13.00
- AVG Volume (30 Days)
- NUVB 2.9M
- SXC 905.7K
- Earning Date
- NUVB 03-06-2025
- SXC 04-30-2025
- Dividend Yield
- NUVB N/A
- SXC 5.21%
- EPS Growth
- NUVB N/A
- SXC 64.98
- EPS
- NUVB N/A
- SXC 1.12
- Revenue
- NUVB $7,873,000.00
- SXC $1,935,400,000.00
- Revenue This Year
- NUVB $47.99
- SXC N/A
- Revenue Next Year
- NUVB $551.81
- SXC $3.70
- P/E Ratio
- NUVB N/A
- SXC $8.22
- Revenue Growth
- NUVB N/A
- SXC N/A
- 52 Week Low
- NUVB $1.70
- SXC $7.47
- 52 Week High
- NUVB $3.97
- SXC $12.82
- Technical
- Relative Strength Index (RSI)
- NUVB 34.81
- SXC 47.30
- Support Level
- NUVB $1.85
- SXC $9.14
- Resistance Level
- NUVB $2.04
- SXC $9.45
- Average True Range (ATR)
- NUVB 0.13
- SXC 0.24
- MACD
- NUVB -0.01
- SXC 0.03
- Stochastic Oscillator
- NUVB 9.66
- SXC 50.89
About NUVB Nuvation Bio Inc.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. The company's clinical-stage product candidate is NUV-868, a BD2-selective oral small molecule BET inhibitor. NUV-868 inhibits the protein BRD4, a key member of the BET family that epigenetically regulates a number of important proteins that control tumor growth and differentiation, including oncogenes such as c-myc. Notably, BET proteins have critical biological functions and are found to be altered in many human cancers. It is also developing its proprietary, small molecule Drug-Drug Conjugate (DDC) platform, a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies with parallels to Antibody-Drug Conjugates (ADCs).
About SXC SunCoke Energy Inc.
SunCoke Energy Inc operates as an independent producer of coke in the Americas. The company operates through three segments: Domestic Coke, Brazil Coke, and Logistics. It offers metallurgical and thermal coal. The company also provides handling and/or mixing services to steel, coke, electric utility, coal producing, and other manufacturing-based customers.